

# QSAR Study on Some Antirhino/Enteroviral Vinylacetylene Benzimidazoles

Shovanlal Gayen, Bikash Debnath, and Tarun Jha\*

Department of Pharmaceutical Technology, Division of Medicinal and Pharmaceutical Chemistry,  
P. O. Box 170 20, Jadavpur University, Kolkata 700 032, India

Received xxx; Preprint published xxx; Accepted xxx ; Published xxx

---

*Internet Electron. J. Mol. Des.* 2003, 2, 000–000

## Abstract

**Motivation.** Quantitative Structure-Activity Relationship (QSAR) Study on some vinylacetylene benzimidazoles was performed using topological indices and physicochemical parameters to identify and distinguish the pharmacophoric atoms as well as required physicochemical properties for their antiviral activity and cellular toxicity tested against human rhinovirus –14 (HRV-14).

**Method.** Correlation Analysis and Multiple Linear Regression (MLR) Analysis have been carried out to derive best QSAR models giving important information at atomic/submolecular level.

**Results.** The present communication shows that the fragment/atoms responsible for the antiviral activity and cellular toxicity of vinylacetylene benzimidazoles are not the same. The atom numbers 7, 8, 9, 22, 23, 24, 25 and 26 are important and only selective for cellular toxicity where as atom numbers 12 and 13 are only selective to antiviral activity. The hydrophilicity of *p*-substituents of the phenyl ring A has selective advantageous effect on the antiviral activity.

**Conclusions.** Electrotopological State Atom (ETSA) index is a valuable tool in exploring the pharmacophoric atoms.

**Keywords.** vinylacetylene benzimidazoles; antirhino/enteroviral activity; QSAR; ETSA index; pharmacophore.

---

## Abbreviations and notations

ETSA, electrotopological state atom  
HRV-14, human rhinovirus-14

MLR, multiple linear regression  
QSAR, quantitative structure-activity relationships

---

\* Correspondence author; phone: 91-33-2414 6677; fax: 91-33-2414 6677; E-mail: [tjjupharm@yahoo.com](mailto:tjjupharm@yahoo.com)

## 1 INTRODUCTION

Vinylacetylene benzimidazole derivatives are the recent addition to antiviral therapy to treat common cold and possess potency and broad spectrum of activity against rhinovirus (110 serotypes) as well as enterovirus (68 serotypes) [1-3]. About 25 years ago, the two compounds Enviroxime and Enviradene [4-5] in benzimidazoles series were reported as antirhino/enteroviral agents from Lilly Research Laboratories. But due to the side effect like emesis in case of Enviroxime and poor peak plasma levels in case of Enviradene [6], a series of Vinylacetylene benzimidazole was made to find an orally bioavailable antiviral drug for the treatment of rhino/enteroviral infections. Some of the compounds of this class have shown good oral bioavailability and antiviral potency.


Vinylacetylene benzimidazoles have the same mechanism of action as Enviroxime [2], revealed by a Cross-sensitivity study with Enviroxime-derived mutants but the detailed mechanism of action of this class remain unclear due to the absence of knowledge of the actual molecular target. However B. A. Heinz *et al* [7] reported that Enviroxime may target the 3A coding region of rhinovirus and poliovirus and it preferentially inhibits synthesis of the viral plus-strand RNA synthesis determined by dot blot analysis of RNA from poliovirus-infected cells. It was also reported that Enviroxime resistance involve two domains within 3A and the amino acid at position 30 is important to determine drug resistance [8].

The present communication is an attempt to quantitatively consider the chemical structural variations required or responsible for the antiviral activity and cellular toxicity of the vinylacetylene benzimidazole derivatives reported by M. J. Tebbe *et al* [3] as a part of our composite program of rational drug design [9-20]. Both physicochemical parameters and electrotopological state atom (ETSA) index [21-25] of some common atoms are used in the Quantitative Structure-Activity Relationship (QSAR) study. Increasing use of this topological index has demonstrated its importance in specifying essential fragments of molecules in QSAR studies. The information generated by this index is focussed at the atom level or on the sub-molecular fragments of the molecular skeleton. Thus, it is possible to exploit pharmacophoric atoms for a particular activity in a particular series of molecules by using ETSA indices in the QSAR studies. In the present study, the ability of the indices to shed light on a pharmacophore governing a particular biological activity is illustrated.

## 2 MATERIALS AND METHODS

The general structure of vinylacetylene benzimidazoles (n=18) considered in the present communication is presented in Figure1 and their observed activities are listed in Table 1. For the

development of 2-D QSAR model the average of ETSA indices of different common atoms and physicochemical parameter like hydrophobicity ( $\pi$ ) of the *p*-substituents of the phenyl ring (A) are used. The values are listed in Table 1. The values of the hydrophobicity parameter are taken from reference [21] and ETSA indices [22-25] are calculated by ‘mouse’, a computer program developed in our laboratory. Before the calculation, the atoms of the molecule are numbered consecutively keeping the serial number of atoms same in all the molecules (Figure 1).



**Figure 1.** General structure of vinylacetylene benzimidazoles

ETSA index is an important tool to uncover a functional region of molecule with potential as a pharmacophore [26]. In E-state formalism an initial consideration was taken that every atom in a molecule is different from other atoms in the molecule except where atoms mapped on to each other through a symmetry operation, due to the difference in electronic and topological environment. The E-state index ( $S_i$ ) of an atom ( $i$ ) in a molecule is composed of an intrinsic state ( $I_i$ ) and the perturbation effect ( $\Delta_{ij}$ ). The general expression of the intrinsic state value of atom ( $i$ ) in  $N$  row of the periodic table is given as

$$I_i = [((2/N)^2 \delta^v + 1) / \delta], \quad (1)$$

$\delta^v$  = number of valence electron – number of hydrogen atom attached,

$\delta$  = number of sigma electron – number of hydrogen atom attached

The information encoded into the atom intrinsic value is of both electronic and topological. The count of pi and lone pair electrons ( $\delta^v$ ) gives important electronic information because electrons occupying these orbitals are more reactive and closely associated with long-range non-covalent intermolecular interaction such as drug-receptor encounters. The important topological attribute is the relative degree of mantle atom or buried atom status, encoded by the number of skeletal neighbours ( $\delta$ ). The general expression for the perturbation effect as follows:

$$\Delta_{ij} = \sum (I_i - I_j) / r_{ij}^2 \quad (2)$$

in which  $r_{ij}$  is the topological distance in the shortest path between the atoms, given as the number  $i$  and  $j$ . Thus, the ETSA index, derived from both the electronic and topological structure

information from all other atoms within the structure, is calculated as

$$S_i = I_i + \Delta_{ij} \quad (3)$$

In the QSAR study negative of logarithmic scale of antiviral activity ( $pIC_{50}$ ) and cellular toxicity ( $pTC_{50}$ ) against human rhinovirus-14 (HRV-14) were considered as dependent parameters. Regression analysis is done using software 'Statistica'. Correlation analysis of ETSA indices and physicochemical parameters were carried out. The auto-correlated parameters were eliminated stepwise through a careful observation. All possible combinations of parameters were considered. The statistical quality of the regression equations were justified by parameters like, correlation coefficient (R), percentage of explained variance (%EV), adjusted  $R^2$  ( $R^2_A$ ), variance ratio (F), standard error of estimate (S.E.E) All the final equations have regression coefficients, intercepts and variance ratio (F) significant to more than 95% level. Use of more than one variable in the multivariate equation was justified by autocorrelation study. The predictive powers of the equation are validated by Leave-one-out (LOO-) cross validation method [27]. Predicted residual sum of square (PRESS), total sum of squares (SSY), cross-validated  $R^2$  ( $R^2_{CV}$ ), standard error of PRESS ( $S_{PRESS}$ ) and predictive standard error or uncertainty factor (P.S.E) for the final equations are considered for the validation of the models.

### 3 RESULTS AND DISCUSSION

The E-state indices were calculated for each common atoms in the set and attempt was done to regress [28-30] individually and in multiples against the  $pIC_{50}$  and  $pTC_{50}$  values for the 18 vinylacetylene benzimidazoles.

From the autocorrelation study, it was found that ETSA indices of atom no 11-21 have higher individual correlation to  $pIC_{50}$  values and they were highly auto-correlated, so cannot be used together in a single QSAR model. It is obvious that QSAR model using one of these ETSA indices may loose some information regarding the pharmacophoric requirements for the antirhino/enteroviral activity. To accommodate these ETSA indices in a single QSAR equation as an independent parameter, an average ( $S_{av1}$ ) of these was taken and the resultant model yielded statistical information as follows

$$pIC_{50} = -2.447 (\pm 0.546) + 2.682 (\pm 0.454) S_{av1} \quad (4)$$

$n = 18$ ;  $R = 0.828$ ;  $\%EV = 68.598$ ;  $R^2_A = 0.666$ ;  $F_{(1,16)} = 34.953$ ;  $p < 0.000$ ;  $S.E.E. = 0.279$

$PRESS = 1.485$ ;  $SSY = 2.980$ ;  $R^2_{CV} = 0.502$ ;  $S_{PRESS} = 0.315$ ;  $P.S.E = 0.287$ .

where  $n$  is the number of data points,  $R$  is correlation coefficient. %EV,  $R^2_A$ ,  $F$ ,  $p$ , S.E.E. PRESS, SSY,  $R^2_{CV}$ ,  $S_{PRESS}$ , P.S.E. are percentage of explained variance, adjusted  $R^2$ , ratio between the variances of observed and calculated activities, probability factor related to  $F$ -ratio, standard error of estimate, predicted residual sum of squares, total sum of squares, cross validated  $R^2$  and standard error of PRESS respectively. Quantities in parenthesis are the corresponding standard deviations of the coefficients.

The physicochemical parameters like electronic, molar refractivity, hydrophobicity ( $\pi_{pA}$ ) were taken for the  $p$ - substituents of phenyl ring A in vinylacetylene benzimidazole and attempt was made whether they can be used along with  $S_{av1}$ . It was found that only hydrophobicity parameter could be used along with  $S_{av1}$  and yielded the model (5).

$$pIC_{50} = -2.528 (\pm 0.509) + 2.791 (\pm 0.426) S_{av1} - 0.441 (\pm 0.235) \pi_{pA} \quad (5)$$

$n = 18$ ;  $R = 0.864$ ; %EV = 74.582;  $R^2_A = 0.712$ ;  $F_{(2,15)} = 22.007$ ;  $p < 0.000$ ; S.E.E. = 0.259

PRESS = 1.328; SSY = 2.980;  $R^2_{CV} = 0.554$ ;  $S_{PRESS} = 0.298$ ; P.S.E = 0.272.

One compound (Compd no **18**) in the dataset, where the acetylene moiety is methyl substituted and another compound (Compd no **14**) where  $m$ -Cl substituent in the phenyl ring A may act indirectly or through a different mechanism of action, may behave as outliers. After deleting the compounds **14**, **18** the final QSAR model is as follows

$$pIC_{50} = -2.813 (\pm 0.406) + 3.092 (\pm 0.344) S_{av1} - 0.562 (\pm 0.187) \pi_{pA} \quad (6)$$

$n = 16$ ; DC = **14,18**;  $R = 0.930$ ; %EV = 86.44;  $R^2_A = 0.844$ ;  $F_{(2,13)} = 41.448$ ;  $p < 0.000$ ; S.E.E. = 0.202

PRESS = 0.698; SSY = 3.926;  $R^2_{CV} = 0.822$ ;  $S_{PRESS} = 0.232$ ; P.S.E = 0.209.

Where DC refers to the deleted compounds behaves as outliers. It is clearly revealed that deletions of outliers significantly improve the statistical quality of QSAR model (5), where the correlation coefficient ( $R$ ) increases by about 0.7 units. The predictive power of the equation (6) is found good as the cross-validated  $R^2$  value  $> 0.7$ . The model explains up to 86.44% of the variation of the antiviral activity. The equation gives lower values of PRESS,  $S_{PRESS}$ , which ensure that optimum number of compounds are taken and there is no over prediction in the model. The equation model reveals that benzimidazole moiety along with atom no 20 and 21 is strong contributor to the antiviral activity of these type of compounds. The equation clearly suggests that higher value of  $S_{av1}$  corresponds to higher antiviral activity as evidenced by the positive regression coefficient in the equation. Another important feature in the equation model is the relationship of antiviral activity to the hydrophobicity parameter  $\pi_{pA}$ . The negative regression coefficient in the equation clearly demonstrates that increase of hydrophobicity of the  $p$ - substitution of the phenyl ring A has

detrimental effect to the activity. So lower hydrophobic rather hydrophilic substitutions at this position is preferable for the antiviral activity. The ETSA index  $S_{av1}$  carries the electronic and topological informations of the substituent pattern of the benzimidazole moiety for the antiviral activity. Thus substituent pattern in the benzimidazole moiety should be such that will increase the value of  $S_{av1}$ . More electronegative substituents such as fluorine in the benzimidazole moiety are destructive to the antiviral activity. These relationships between substitution patterns on benzimidazole moiety suggest the possibility of a pharmacophore feature associated with the moiety.

When the ETSA indices and the physicochemical parameters were correlated with the  $pTC_{50}$  (negative logarithm of  $TC_{50}$  against HRV-14) values the ETSA indices of atoms 7-9 and 14-26 are highly auto-correlated and in a similar way a composite ETSA index  $S_{av2}$  was formed by taking average of these indices. ETSA index of atom no 2 ( $S_2$ ) can be used with  $S_{av2}$  that yielded the following equation given below.

$$pTC_{50} = -6.988 (\pm 1.562) + 2.333 (\pm 0.674) S_{av2} + 0.267 (\pm 0.086) S_2 \quad (7)$$

$$n = 16; R = 0.840; \%EV = 70.550; R^2_A = 0.660; F_{(2,13)} = 15.571; p < 0.000; S.E.E. = 0.255$$

$$PRESS = 1.228; SSY = 2.862; R^2_{CV} = 0.571; S_{PRESS} = 0.307; P.S.E = 0.277.$$

After deletion of the compound no **14** (DC= **14**), which may act in a different mechanism and considered as an outlier, the final equation obtained as follows

$$pTC_{50} = -7.493 (\pm 1.371) + 2.552 (\pm 0.592) S_{av2} + 0.283 (\pm 0.075) S_2 \quad (8)$$

$$n = 15; DC = \mathbf{14}; R = 0.891; \%EV = 79.341; R^2_A = 0.759; F_{(2,12)} = 23.043; p < 0.000; S.E.E. = 0.220$$

$$PRESS = 0.899; SSY = 2.824; R^2_{CV} = 0.682; S_{PRESS} = 0.274; P.S.E = 0.245.$$


The resultant model (8) is considered to be the best model in case of  $pTC_{50}$ , which explains 79.341% of the variation of the biological activity data. The atoms associated with  $S_{av2}$  and  $S_2$  constitute the potential region for the cellular toxicity. The equation clearly explains that lower cellular toxicity corresponds to lower value of  $S_2$  and  $S_{av2}$  indices as evidenced by the positive regression coefficients.

The final equations (6) and (8) obtained are considered statistically significant because the associated probability values  $< 0.05$  and therefore variance ratio (F) is statistically significant. Use of more than one variable in the multivariate equations was justified by the autocorrelation study. The correlation matrices for the final equations (6) and (8) are presented in Table 2. The student t-values and probability-p values of all the equations are given in Table 3. The predictive power of the equations were confirmed by LOO-cross-validation method, where one compound is deleted at once and prediction of the activity of the deleted compound is made based on the QSAR model. The

process is repeated after elimination of another compound until all of the compounds have been deleted at once. The observed (Obs), calculated (Calc), LOO- predicted (Pred) and predicted residual (Pres) values of the two final equations (6) and (8) are shown in Table 4.

## 4 CONCLUSIONS

The present study illustrates the ability of ETSA indices to identify a functional region of a molecule with potential as a pharmacophore for a particular activity. The two final statistically robust QSAR models (equation no 6 and 8) contain composite ETSA indices  $S_{av1}$  and  $S_{av2}$  respectively, clearly demonstrate that the atoms associated with these indices may form the possible pharmacophore moiety inherent in a set of closely related structures for the desired activity. The pharmacophoric atoms in the vinylacetylene benzimidazoles for the antiviral activity and the cellular toxicity against HRV-14 are presented in Figure 2. An important feature which is also revealed, is that by changing the substitution pattern at the phenyl ring A in vinylacetylene benzimidazole derivatives, it may be possible to produce better active compounds having lower cellular toxicity. This selectivity of higher antiviral potency and lower toxicity may be possible by introducing hydrophilic substitutions at *p*- position of the ring and substitutions capable to lower the value of ETSA index of atom no 2 ( $S_2$ ) at *o*-position of the ring. The substitutions, able to increase the value of  $S_{av1}$  and decrease the value of  $S_{av2}$  at the remaining part of the vinylacetylene benzimidazole structure confer further this type of selectivity. This useful information encoded by the final QSAR models may be communicated to synthetic chemists for the development of biologically safe new compound having the potential antiviral activity to treat rhino/enteroviral infections.



**Figure 2.** Possible pharmacophore for the antiviral activity and cellular toxicity of vinylacetylene benzimidazoles

## Acknowledgment

Authors are thankful to the authority of Jadavpur University for awarding a minor research project from Unassigned Grant of University Grants Commission.

## 5 REFERENCES

- [1] M. J. Tebbe, C. B. Jensen, W. A. Spitzer, R. B. Franklin, M. C. George and D. L. Phillips, The Effects of Antirhino- and Enteroviral Vinylacetylene Benzimidazoles on Cytochrome P450 Function and hepatic Porphyrin Levels in Mice, *Antiviral Res.* **1999**, *42*, 25-33.
- [2] F. Victor, T. J. Brown, K. Campanale, B. A. Heinz, L. A. Shipley, K. S. Su, J. Tang, L. M. Vance and W. A. Spitzer, Synthesis, Antiviral Activity and Biological Properties of Vinylacetylene Analogs of Enviroxime, *J. Med. Chem.* **1997**, *40*, 1511-1518.
- [3] M. J. Tebbe, W. A. Spitzer, F. Victor, S. C. Miller, C. C. Lee, T. R. Sr. Sattelberg, E. McKinney and J. C. Tang,, Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Level in Mice, *J. Med. Chem.* **1997**, *40*, 3937-3946.
- [4] D. C. DeLong and S. E. Reed, Inhibition of Rhinovirus Replication in Organ Culture by a Potential Antiviral Drug, *J. Infect. Dis.* **1980**, *141*, 87-91.
- [5] E. C. Herrmann, J. A. Herrmann, and D. C. DeLongJ, comparison of the antiviral effects of substituted Benzimidazoles and Guanine in Vitro and in Vivo, *antiviral Res.* **1981**, *1*, 301-314.
- [6] F. D. Miller, A. S. Monto, D. C. Delong, A. Exelby, E. R. Bryan and S. Srivastava, Controlled Trial of Enviroxime against Natural Rhinovirus Infections in a Community, *Antimicrob. Agents Chemother.* **1985**, *27*, 102-106.
- [7] B. A. Heinz and L. M. Vance, The Antiviral Compound Enviroxime Targets the 3A Coding Region of Rhinovirus and Poliovirus, *J. Virol.* **1995**, *69*, 4189-4197.
- [8] B. A. Heinz and L. M. vance, Sequence Determinats of 3A-Mediated Resistance to Enviroxime in Rhinovirus and Enterovirus, *J. Virol.* **1996**, *70*, 4854-4857.
- [9] S. K. Purkayastha, T. Jha, D. K. Pal and A. U. De, Possible antineoplastic agents part XIII-synthesis, biological evaluation and QSAR studies of some 1-(substituted benzenesulphonyl)-5-oxopyrrolidine-2-carboxylic acid derivatives, *Anticancer Drug Des.* **1993**, *8*, 95-100.
- [10] K. Srikanth, C. A. Kumar, D. Goswami, A. U. De and T. Jha, Quantitative structure activity relationship (QSAR) studies of some substituted benzenesulphonyl glutamines as tumor suppressors, *Ind. J. Biochem.Biophys.* **2001**, *38*, 120-123.
- [11] K. Srikanth, B. Debnath and T. Jha, Synthesis, biological evaluation and QSAR study on antitumor activity of 1,5-*N, N'*- distubuted-2-(substituted benzenesulphonyl) glutamamides, *Bioorg. Med. Chem.* **2002**, *10*, 1841-1854.
- [12] K. Srikanth, B. Debnath and T. Jha, QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d] pyrimidine nucleoside analogs using Hansch approach, *Bioorg. Med. Chem. Lett.*, **2002**, *12*, 899-902.
- [13] K. Srikanth, C. A. Kumar, B. Ghosh and T. Jha, Synthesis, screening and quantitative structure-activity relationship (QSAR) studies on some glutamine analogues for possible anticancer activity, *Bioorg. Med. Chem.* **2002**, *10*, 2119-2131.
- [14] B. Debnath, K. Srikanth, S. Banarjee and T. Jha, 1,5-*N, N'*-Distibuted-2-(Substituted Benzenesulphonyl)-Glutamamides as Antitumor Agents. Part 2. Synthesis, Biological Activity and QSAR Study, *Internet Electron. J. Mol. Des.* **2002**, *1*, 488-502, <http://www.biochempress.com>
- [15] B. Debnath, S. P. Vishnoi, B. Sa and T. Jha, QSAR study on some dihydrofolate reductase inhibitors, *Internet Electron. J. Mol. Des.* **2003**, *1*, 128-136. <http://www.biochempress.com>
- [16] B. Debnath, S. Samanta, K. Roy and T. Jha, QSAR study on some *p*-arylthio cinnamides as antagonists of biochemical ICAM-1/LFA-1 interaction and ICAM-1/JY-8 cell adhesion in relation to anti-inflammatory activity, *Bioorg. Med. Chem.* **2003**, *11*, 1615-1619.
- [17] B. Debnath, S. Gayen, S. K. Naskar, K. Roy and T. Jha, QSAR Study of some Azidopyridinyl Neonicotinoids Insecticides for Their Selective Affinity Towards the Drosophilla Nicotinic Receptor over Mammalian  $\alpha_4\beta_2$  Receptor Using Electrotopological State Atom Index, *Drug Des.Discov.* **In Press**.
- [18] B. Debnath, S. Samanta, S. K. Naskar, K. Roy and T. Jha, , *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2837-2842.
- [19] T. Jha, B. Debnath, S. Samanta and A. U. De, QSAR Study on Some substituted Glutamine analogs As Anticancer Agents. *Internet Electron. J. Mol. Des.* **2003**, *2*, 539-545. <http://www.biochempress.com>
- [20] B. Debnath, S. Gayen, S. Samanta and T. Jha, QSAR Study on Some Pyridoacridine Ascididemin Analogs as Anti-tumor Agents. *Bioorg. Med. Chem.* **In Press**.



- [21] C. Hansch and A. Leo, *Substituent constants for correlation analysis in chemistry and biology*, Wiley & Sons, New York 1979.
- [22] L. B. Kier and L. H. Hall, *Molecular Connectivity: intermolecular accessibility and encounter simulation*, *J. Mol. Graph Mod.* **2001**, *20*, 76-83.
- [23] K. Rose, L. H. Hall, and L. B. Kier, *Modelling Blood- Brain Barrier Partitioning Using Electrotopological state*, *J. Chem. Inf. Comput. Sci.* **2002**, *42*, 651-666.
- [24] L. B. Kier and L. H. Hall, *An Electrotopological-State Index for atoms in Molecules*, *Pharmaceutical Res.* **1990**, *7*, 801-807.
- [25] K. Roy, D. K. Pal and C. Sengupta, *Hansch Analysis of Antimalarial Cyclic Peroxy Ketals with Physicochemical and Electrotopological Parameters*, *Drug Des. Discov.* **2000**, *17*, 183-190.
- [26] C. de Gregorio, L. B. Kier and L. H. Hall, *QSAR modeling with the electrotopological state indices: Corticosteroids*, *J. Comput.-Aid. Mol. Des.* **1998**, *12*, 557-561.
- [27] I. V. Tetko, V. Y. Tanchuk and A. E. Villa, *Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices*, *J. Chem. Inf. Comput. Sci.* **2001**, *41*, 1407-1421.
- [28] G. W. Snedecor and W. G. Cochran, *Statistical Methods*, Oxford & IBH, New Delhi, 1967.
- [29] D. C. Montgomery (Ed.) *Design and Analysis of experiments*, John Wiley & sons, 1997, New York.
- [30] E. J. Lien, *Quantitative correlations using Multiple Regression and substitution constants*; in: *Drug design*, E. J. Ariens, Academic, 1975, New York.

**Table 1.** ETSA indices, hydrophobic parameters and biological activity data of vinylacetylene benzimidazoles

Cpd	R <sub>1</sub>	R <sub>2</sub>	X	Y	S <sub>2</sub>	S <sub>av1</sub>	S <sub>av2</sub>	π <sub>pA</sub>	IC <sub>50</sub>	pIC <sub>50</sub>	TC <sub>50</sub>	pTC <sub>50</sub>
<b>1</b>	H	H	H	CH	1.948	1.329	2.459	0.000	0.094	1.027	11	-1.041
<b>2</b>	3-F	H	H	CH	1.365	1.246	2.380	0.000	0.060	1.222	5.3	-0.724
<b>3</b>	2-F	H	H	CH	-0.428	1.220	2.351	0.000	0.092	1.036	66	-1.820
<b>4</b>	4-F	H	H	CH	1.610	1.263	2.398	0.140	0.13	0.886	5.8	-0.763
<b>5</b>	2,5-di F	H	H	CH	-0.661	1.137	2.272	0.000	0.11	0.959	63	-1.799
<b>6</b>	3,5-di F	H	H	CH	1.146	1.163	2.300	0.000	0.17	0.770	32	-1.505
<b>7</b>	3,4-di F	H	H	CH	1.027	1.181	2.318	0.140	0.19	0.721	19	-1.279
<b>8</b>	3-F, 4-OMe	H	H	CH	1.308	1.233	2.373	-0.020	0.061	1.215	5.5	-0.740
<b>9</b>	4-OMe	H	H	CH	1.891	1.316	2.453	-0.020	0.059	1.229	5.2	-0.716
<b>10</b>	4-Me	H	H	CH	1.985	1.333	2.468	0.560	0.075	1.125	5.7	-0.756
<b>11</b>	4-NMe <sub>2</sub>	H	H	CH	1.985	1.333	2.473	0.180	0.117	0.932	5.3	-0.724
<b>12</b>	3-CF <sub>3</sub>	H	H	CH	0.990	1.135	2.281	0.000	0.40	0.398	>100	–
<b>13</b>	4-OCF <sub>3</sub>	H	H	CH	1.421	1.182	2.330	1.040	0.55	0.260	18	-1.255
<b>14</b>	3-Cl	H	H	CH	1.797	1.303	2.438	0.000	0.21	0.678	20	-1.301
<b>15</b>	H	5-F	H	CH	1.795	0.850	2.268	0.000	1.5	-0.176	13	-1.114
<b>16</b>	H	7-F	H	CH	1.795	0.804	2.082	0.000	2.8	-0.447	57	-1.756
<b>17</b>	5-F	H	H	N	1.721	1.202	2.535	0.000	0.061	1.215	>100	–
<b>18</b>	5-F	H	CH <sub>3</sub>	CH	1.771	1.275	2.442	0.000	0.26	0.585	3.1	-0.491

**Table 2.** Correlation matrices for the final equations (6) and (8)

Eqn (6)	$\pi_{pA}$	$S_{av1}$	$pIC_{50}$	Eqn (8)	$S_2$	$S_{av2}$	$pTC_{50}$
$\pi_{pA}$	1.00	0.18	-.15	$S_2$	1.00	0.29	0.69
$S_{av1}$		1.00	0.88	$S_{av2}$		1.00	0.74
$pIC_{50}$			1.00	$pTC_{50}$			1.00

**Table 3.** t- and p- values of all QSAR equations

Eq no	Intercept/Parameter	t-value	p-value	Eq no	Intercept/Parameter	t-value	p-value
(4)	Intercept	-4.482	0.000	(7)	Intercept	-4.472	0.001
	$S_{av1}$	5.912	0.000		$S_2$	3.100	0.008
					$S_{av2}$	3.460	0.004
(5)	Intercept	-4.965	0.000	(8)	Intercept	-5.468	0.000
	$\pi_{pA}$	-1.879	0.080		$S_2$	3.776	0.003
	$S_{av1}$	6.560	0.000		$S_{av2}$	4.315	0.001
(6)	Intercept	-6.923	0.000				
	$\pi_{pA}$	-3.010	0.010				
	$S_{av1}$	8.992	0.000				

**Table 4.** Observed (Obs), calculated (Calc), residual (Res), LOO-predicted (Pred), and predicted residual (Pres) values of equations (6) and (8)

Cpd	Obs	Obs	Calc	Equation (6)			Calc	Equation (8)		
	pIC <sub>50</sub>	pTC <sub>50</sub>		Res	Pred	Pres		Res	Pred	Pres
<b>1</b>	1.027	-1.041	1.295	-0.268	1.341	-0.314	-0.665	-0.376	-0.597	-0.44
<b>2</b>	1.222	-0.724	1.039	0.183	1.020	0.202	-1.033	0.309	-1.056	0.332
<b>3</b>	1.036	-1.820	0.958	0.078	0.951	0.084	-1.612	-0.207	-1.464	-0.356
<b>4</b>	0.886	-0.763	1.015	-0.129	1.026	-0.140	-0.918	0.155	-0.931	0.168
<b>5</b>	0.959	-1.799	0.702	0.257	0.680	0.279	-1.881	0.082	-1.960	0.161
<b>6</b>	0.770	-1.505	0.783	-0.013	0.784	-0.014	-1.298	-0.207	-1.278	-0.227
<b>7</b>	0.721	-1.279	0.758	-0.037	0.761	-0.040	-1.285	0.007	-1.286	0.007
<b>8</b>	1.215	-0.740	1.009	0.205	0.989	0.226	-1.066	0.325	-1.089	0.349
<b>9</b>	1.229	-0.716	1.266	-0.037	1.273	-0.044	-0.697	-0.019	-0.694	-0.022
<b>10</b>	1.125	-0.756	0.995	0.130	0.951	0.174	-0.634	-0.122	-0.609	-0.147
<b>11</b>	0.932	-0.724	1.207	-0.275	1.246	-0.314	-0.619	-0.105	-0.598	-0.126
<b>12</b>	0.398	–	0.696	-0.298	0.722	-0.324	–	–	–	–
<b>13</b>	0.260	-1.255	0.257	0.003	0.247	0.013	-1.145	-0.110	-1.136	-0.118
<b>14</b>	0.678	-1.301	–	–	–	–	–	–	–	–
<b>15</b>	-0.176	-1.114	-0.185	0.009	-0.190	0.014	-1.197	0.083	-1.214	0.100
<b>16</b>	-0.447	-1.756	-0.327	-0.120	-0.223	-0.224	-1.672	-0.084	-1.469	-0.287
<b>17</b>	1.215	–	0.903	-0.311	0.877	0.338	–	–	–	–
<b>18</b>	0.585	-0.491	–	–	–	–	-0.759	0.268	-0.796	0.305